According to GuruFocus Insider Data, the recent CFO sales were: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc. and Thermo Fisher Scientific Inc.
Facebook Inc. (FB, Financial): CFO David A. Ebersman Sold 23,400 Shares
On 02/05/2014, CFO David A. Ebersman sold 23,400 shares at an average price of $62.36. The price of the stock has increased by 3.14% since. Facebook Inc. has a market cap of $164 billion and its shares were traded at around $64.32. The company has a P/E ratio of 159.20 and P/S ratio of 24.46.
Facebook Inc. announced their 2013 fourth quarter results with revenues of $2.59 billion and gross profit of $2.1 billion; the net income was $520 million. The 2013 total revenue for Facebook Inc. was $7.87 billion, a 55% increase from the 2012 total revenue. The 2013 gross profit was $6 billion, a 61% increase from the 2012 gross profit. The 2013 net income was $1.5 billion.
On 01/31/2014, Director Marc L. Andreessen sold 1,274,869 shares at an average price of $61.63. The price of the stock has increased by 5.05% since. On 01/29/2014, Chief Accounting Officer Jas Athwal sold 500 shares at an average price of $54.60. The price of the stock has increased by 17.8% since. On 12/26/2013, COB and CEO, 10% Owner Mark Zuckerberg sold 41,350,000 shares at an average price of $55.05. The price of the stock has increased by 16.84% since.
Cardinal Health Inc. (CAH, Financial): CFO Jeffrey William Henderson Sold 253,190 Shares
On 02/03/2014, CFO Jeffrey William Henderson sold 253,190 shares at an average price of $67.54. The price of the stock has increased by 0.52% since. Cardinal Health Inc. has a market cap of $23.16 billion and its shares were traded at around $67.54. The company has a P/E ratio of 58.60 and P/S ratio of 0.23; additionally, Cardinal Health Inc. has a dividend yield of 1.75%.
Cardinal Health Inc. announced their 2013 third quarter results with revenues of $24.5 billion and gross profit of $1.26 billion; the net income was $339 million. The 2013 total revenue for Cardinal Health Inc. was $101 billion, a 6% decrease from the 2012 total revenue. The 2013 gross profit was $4.9 billion, an 8% increase from the 2012 gross profit. The 2013 net income was $334 million.
On 02/05/2014, Director Calvin Darden sold 5,282 shares at an average price of $65.43. The price of the stock has increased by 3.22% since. On 02/05/2014, Director Gregory B. Kenny sold 18,175 shares at an average price of $65.39. The price of the stock has increased by 3.29% since. On 11/11/2013, Chairman and CEO George S. Barrett sold 200,000 shares at an average price of $62.71. The price of the stock has increased by 7.7% since.
Alexion Pharmaceuticals Inc. (ALXN, Financial): EVP and CFO Vikas Sinha Sold 3,552 Shares
On 02/04/2014, EVP and CFO Vikas Sinha sold 3,552 shares at an average price of $154.47. The price of the stock has increased by 5.93% since. Alexion Pharmaceuticals Inc. has a market cap of $32.08 billion and its shares were traded at around $163.63. The company has a P/E ratio of 92.80 and P/S ratio of 22.89; over the past five years, Alexion Pharmaceuticals Inc. had an annual average earnings growth of 68.50%.
Alexion Pharmaceuticals Inc. announced their 2013 third quarter results with revenues of $400.4 million and gross profit of $349 million; the net income was $93.79 million. The 2012 total revenue for Alexion Pharmaceuticals Inc. was $1.1 billion, a 45% increase from the 2011 total revenue. The 2012 gross profit was $1.06 billion, a 54% increase from the 2011 gross profit. The 2012 net income was $254.8 million.
On 02/04/2014, CEO Leonard Bell sold 11,790 shares at an average price of $154.50. The price of the stock has increased by 5.92% since. On 02/03/2014, Director Larry Mathis sold 80,729 shares at an average price of $157.50. The price of the stock has increased by 3.89% since. On 02/03/2014, Director Max Link sold 40,000 shares at an average price of $155.16. The price of the stock has increased by 5.46% since.
Thermo Fisher Scientific Inc. (TMO, Financial): Senior VP and CFO Peter M. Wilver Sold 91,897 Shares
On 02/07/2014, Senior VP and CFO Peter M. Wilver sold 91,897 shares at an average price of $117.77. The price of the stock has increased by 2.22% since. Thermo Fisher Scientific Inc. has a market cap of $42.56 billion and its shares were traded at around $117.77. The company has a P/E ratio of 32.80 and P/S ratio of 3.32 with a dividend yield of 0.51%. Over the past 10 years, Thermo Fisher Scientific Inc. had an annual average earnings growth of 16.60%. GuruFocus rated Thermo Fisher Scientific Inc. the business predictability rank of 4.5-star.
Thermo Fisher Scientific Inc. announced their 2013 third quarter results with revenues of $3.19 billion and gross profit of $1.3 billion; the net income was $317.6 million. The 2012 total revenue for Thermo Fisher Scientific Inc. was $12.5 billion, an 8% increase from the 2011 total revenue. The 2012 gross profit was $5.3 billion, a 10% increase from the 2011 gross profit. The 2012 net income was $1.2 billion.
On 02/06/2014, Director Jim P. Manzi sold 6,000 shares at an average price of $114.26. The price of the stock has increased by 3.07% since. On 02/06/2014, Firector William G. Parrett sold 18,000 shares at an average price of $114.33. The price of the stock has increased by 3.01% since. On 09/16/2013, Executive Vice President Alan J. Malus sold 4,000 shares at an average price of $91.87. The price of the stock has increased by 28.19% since.
